TY - JOUR
T1 - Secukinumab for psoriatic arthritis
T2 - comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis
AU - McInnes, Iain B
AU - Nash, Peter
AU - Ritchlin, Christopher
AU - Choy, Ernest
AU - Kantars, Steve
AU - Thom, Howard
AU - Ghandhi, Kunal
AU - Pricop, Luminita
AU - Jugl, Steffen M
PY - 2018/9/19
Y1 - 2018/9/19
N2 - Aim: A network meta-analysis (NMA) using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (ACR, PASI and PsARC response rates) at 12–16 weeks for secukinumab, adalimumab, apremilast, certolizumab, etanercept, golimumab, infliximab, and ustekinumab. Patients & methods: Trials were identified by systematic review. Separate networks were developed for the full study populations, biologic-naïve patients, and biologic-experienced patients. Results: In the full populations, secukinumab, adalimumab, golimumab and infliximab demonstrated the highest ACR response rates. Secukinumab and infliximab demonstrated the highest PASI response rates, and infliximab and etanercept demonstrated the highest PsARC response rates. Conclusion: In the full populations, secukinumab demonstrated good efficacy across all outcomes. All treatments for active PsA included in this comprehensive NMA demonstrated superiority to placebo.
AB - Aim: A network meta-analysis (NMA) using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (ACR, PASI and PsARC response rates) at 12–16 weeks for secukinumab, adalimumab, apremilast, certolizumab, etanercept, golimumab, infliximab, and ustekinumab. Patients & methods: Trials were identified by systematic review. Separate networks were developed for the full study populations, biologic-naïve patients, and biologic-experienced patients. Results: In the full populations, secukinumab, adalimumab, golimumab and infliximab demonstrated the highest ACR response rates. Secukinumab and infliximab demonstrated the highest PASI response rates, and infliximab and etanercept demonstrated the highest PsARC response rates. Conclusion: In the full populations, secukinumab demonstrated good efficacy across all outcomes. All treatments for active PsA included in this comprehensive NMA demonstrated superiority to placebo.
U2 - 10.2217/cer-2018-0075
DO - 10.2217/cer-2018-0075
M3 - Article (Academic Journal)
C2 - 30230361
SN - 2042-6305
JO - Journal of Comparative Effectiveness Research
JF - Journal of Comparative Effectiveness Research
ER -